Abstract: An optoelectronic package and a method for producing the optoelectronic package are provided. The optoelectronic package includes a carrier, a photonic device, a first encapsulant and a second encapsulant. The photonic device is disposed on the carrier. The first encapsulant covers the carrier and is disposed around the photonic device. The second encapsulant covers the first encapsulant and the photonic device. The first encapsulant has a topmost position and a bottommost position, and the topmost position is not higher than a surface of the photonic device.

Abstract: An electronic device includes a display and an image capture device electronically capturing one or more images of a subject performing an activity. A wireless communication device can electronically transmit the one or more images to a remote electronic device across a network after a Procrustes superimposition operation is performed to compare the subject to a standard. The wireless communication device can electronically receive one or more electronically altered images identifying differences between one or more standard reference locations situated at one or more predefined features of the standard performing the activity and one or more corresponding subject reference locations situated at one or more predefined features of the subject performing the activity. These electronically altered images can be presented on the display of the electronic device to provide corrective feedback to the subject as how to better perform the activity.

Abstract: A magnetic cell biocarrier combined with a powerless bioreactor system comprising a biocarrier, a powerless bioreactor, and a magnetic field device. The biocarrier can detach the cells through temperature regulation and can be adsorbed by the magnetic field device to stabilize at the bottom of the gooseneck cell culture tank; the powerless bioreactor comprises a microinfusion element, a culture fluid collection element, and a gooseneck cell culture tank; the internal space of the gooseneck cell culture tank is interconnected with the microinfusion element and the culture fluid collection element, the microinfusion element slowly injects fresh culture medium When the culture medium in the gooseneck cell culture tank is above an overflow position, the cell metabolites can be automatically discharged to the culture fluid collection element by the interconnected vessels to reduce the risk of cell contamination.

Abstract: A probe for monitoring new bone formation and osseointegration containing an integrin ?5?1 ligand conjugated to a near-infrared fluorescent dye in which the integrin ?5?1 ligand is a cyclic peptide lacking an RGD sequence. Also disclosed is a bone repair and osteogenesis-monitoring probe formed of a bisphosphonate conjugated to a gold nanoparticle, the probe having a size of 1 nm to 10 nm. Further disclosed are two methods for monitoring bone formation, each of which is carried out by administering the above probes and obtaining a near-infrared fluorescence image.

Abstract: An electronic device includes a display and an image capture device electronically capturing one or more images of a subject performing an activity. A wireless communication device can electronically transmit the one or more images to a remote electronic device across a network after a Procrustes superimposition operation is performed to compare the subject to a standard. The wireless communication device can electronically receive one or more electronically altered images identifying differences between one or more standard reference locations situated at one or more predefined features of the standard performing the activity and one or more corresponding subject reference locations situated at one or more predefined features of the subject performing the activity. These electronically altered images can be presented on the display of the electronic device to provide corrective feedback to the subject as how to better perform the activity.

Abstract: A cancer treatment method using a Ni-SOD mimic compound is provided, which includes administrating the Ni-SOD compound to a cancer cell of a cancer. The structure of the Ni-SOD mimic compound is represented as follows: wherein R1 represents H or A-R?; A represents a bond, O or N; L represents acetonitrile, water, or t-butyl isocyanate; R? represents H, unsubstituted or substituted alkyl, polyalkoxy, polydimethylsiloxane, polyurethane or other polymer materials or amino acid groups; R2 represents unsubstituted or substituted alkyl, alkoxy, siloxy, amino, alkylamine or hydrocarbyl groups; R3 represents unsubstituted or substituted amino, alkylamine, oxyalkylamine groups or magnetic nanoparticles attached oxyalkylamine. Ni is bivalent or trivalent.

Abstract: The present disclosure provides a compound for releasing nitric oxide; the compound has the structure of formula (I): The present disclosure also provides a pharmaceutical composition containing the compound of formula (I). The present disclosure further provides a method of releasing nitric oxide, the method includes: administrating the compound of formula (I). The present disclosure also provides a method of treating disease in a patient, the method includes administrating a therapeutically effective amount of the compound of formula (I). The present disclosure also provides the method for synthesizing the compound of formula (I).

Abstract: A client device encodes data into an audio signal and communicates the audio data to an additional client device, which decodes the data from the audio signal. The data is partitioned into characters, which are subsequently partitioned into a plurality of sub-characters. Each sub-character is encoded into a frequency, and multiple frequencies that encode sub-characters are combined by the client device to generate an audio signal. Frequencies encoding sub-characters may be above 16 kilohertz, so the sub-characters are transmitted using frequencies that are inaudible to humans. The audio signal is communicated to an additional client device, which decodes frequencies from the audio signal to sub-characters, which are then combined into characters by the additional client device to generate the data.

Abstract: The present invention provides a compound of formula (I) or the salt thereof: wherein R is at least one selected from the group consisting of unsubstituted C1-4 alkyl, C1-4 alkyl substituted by C6-18 aryl or —OR1, and —C(?O)Z. The compound is a type-S protein kinase inhibitor, which binds to an ATP-binding site and a substrate-recognition site of a protein kinase simultaneously. The present invention further provides a pharmaceutical composition, which includes a compound of formula (I) or a salt and a pharmaceutically acceptable carrier thereof. The present invention further provides a use of a compound of formula (I) or a salt thereof, which is for the manufacture of a protein kinase inhibitor as a drug.

Abstract: The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models. The results have demonstrated how NiSOD-like compounds are likely to work in suppressing abnormal protein aggregation, recovering cell viability, increasing mature neuron number and neurite outgrowth length and protecting dopaminergic cells by reducing oxidative stress or reactive oxygen species in brain tissues.

Abstract: The present invention provides a compound of formula (I) or the salt thereof: wherein R is at least one selected from the group consisting of unsubstituted C1-4 alkyl, C1-4 alkyl substituted by C6-18 aryl or —OR1, and —C(?O)Z. The compound is a type-S protein kinase inhibitor, which binds to an ATP-binding site and a substrate-recognition site of a protein kinase simultaneously. The present invention further provides a pharmaceutical composition, which includes a compound of formula (I) or a salt and a pharmaceutically acceptable carrier thereof. The present invention further provides a use of a compound of formula (I) or a salt thereof, which is for the manufacture of a protein kinase inhibitor as a drug.

Abstract: A client device encodes data into an audio signal and communicates the audio data to an additional client device, which decodes the data from the audio signal. The data is partitioned into characters, which are subsequently partitioned into a plurality of sub-characters. Each sub-character is encoded into a frequency, and multiple frequencies that encode sub-characters are combined by the client device to generate an audio signal. Frequencies encoding sub-characters may be above 16 kilohertz, so the sub-characters are transmitted using frequencies that are inaudible to humans. The audio signal is communicated to an additional client device, which decodes frequencies from the audio signal to sub-characters, which are then combined into characters by the additional client device to generate the data.

Abstract: The accumulation of abnormal proteins in neurodegenerative disorders is considered to induce oxidative stress and lead to cell death. Thus suppression of abnormal protein aggregation and reducing oxidative stress or reactive oxygen species (ROS) are expected to inhibit a wide range of harmful downstream events, providing an observation for identifying the potential prevention and treatment of neurodegenerative disorders comprising spinocerebellar ataxia (SCA), Alzheimer's disease (AD) or Parkinson's disease (PD). In the present invention, there are several cell and animal experiment models for SCA, AD and PD established, and NiSOD-like compounds were applied to these experiment models.

Abstract: A ligand and a metal complex having the ligand are provided. The ligand and a paramagnetic metal ion form a metal complex with high stability, high relaxivity and high biocompatibility. The metal complex of the present invention is applicable to the preparation of MRI contrast agents for detecting atherosclerosis. The MRI contrast agent includes a peptide sequence specific to a matrix metalloprotease, and can be recognized by a pathological thrombocyte to target a specific site, so as to enhance the imaging contrast.

Abstract: A cycloalkyl triamine pentacarboxylate compound coordinating to a metal ion to form a high stability metal complex in serum is provided. The metal complex of the present invention can be used as a contrast agent for magnetic resonance imaging (MRI).

Abstract: A ligand and a metal complex having the ligand are provided. The ligand and a paramagnetic metal ion form a metal complex with high stability, high relaxivity and high biocompatibility. The metal complex of the present invention is applicable to the preparation of MRI contrast agents for detecting atherosclerosis. The MRI contrast agent includes a peptide sequence specific to a matrix metalloprotease, and can be recognized by a pathological thrombocyte to target a specific site, so as to enhance the imaging contrast.

Abstract: A ligand of Formula (I) is provided: wherein A4 represents a hydrogen atom, a nitro group, an amino group, a thiocyanato group, or —Z—Y, in which Z is a divalent linking group and Y is a group derived from a biocompatible molecule, with the proviso that when X is methylene, A4 cannot be a hydrogen atom or a nitro group. A metal complex having the ligand is also provided and is useful as a blood pool contrast agent or a targeting contrast agent.

Abstract: A nanoparticle contains a core including superparamagnetic nanoparticles and having an outer surface, and siloxanyl moieties covalently coupled to the outer surface of the core and having Formula (I): In formula (I): X1 and X2 independently represent methylene, ethylene or propylene; R represents an optionally substituted pyridyl group, or —S—R is a group derived from a targeting ligand containing —SH group and effective to bind specifically with a predetermined targeted cell in an object; n and m independently represent an integer ranging from 1 to 3; and p represents an integer ranging from 9 to 45. The nanoparticles are suitable for use as a magnetic resonance imaging contrast agent.

Abstract: A nanoparticle contains a core including superparamagnetic nanoparticles and having an outer surface, and siloxanyl moieties covalently coupled to the outer surface of the core and having Formula (I): In formula (I): X1 and X2 independently represent methylene, ethylene or propylene; R represents an optionally substituted pyridyl group, or —S—R is a group derived from a targeting ligand containing —SH group and effective to bind specifically with a predetermined targeted cell in an object; n and m independently represent an integer ranging from 1 to 3; and p represents an integer ranging from 9 to 45. The nanoparticles are suitable for use as a magnetic resonance imaging contrast agent.

Abstract: The preparation method of the magnetic nanoparticle (MNP) includes steps of: (a) reacting folic acid (FA) with Pluronic F127 (PF127) to form FA-PF127; (b) reacting poly(acrylic acid) (PAA) with FeCl3 to form PAA-bound iron oxide (PAAIO); and (c) reacting FA-PF127 with PAAIO via N-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC) mediation to form FA-PF127-PAAIO. FA-PF127-PAAIO is nontoxic and shows the superparamagnetic property at room temperature. The Nile red-loaded FA-PF127-PAAIO can be performed as the chemotherapy agent and the contrast agent on magnetic resonance (MR) imaging.